Datapoint: FDA Approves Lilly’s Interchangeable Insulin

November 29

The FDA on Nov. 16 granted Eli Lilly’s Rezvoglar, a biosimilar to Sanofi’s insulin Lantus, interchangeability with its reference product. This approval marks the second interchangeable copy of Lantus — Viatris and Biocon Biologics’ Semglee hit the market in November 2021. For the treatment of type 2 diabetes, Semglee currently holds covered or better status for 60% of all insured lives, to Lantus’ 71%.

SOURCE: MMIT Analytics, as of 11/21/22

0 Comments

Datapoint

Jinghong Chen Reporter

Jinghong has been producing infographics and data stories on employer-sponsored insurance, public health insurance programs and prescription drug coverage for AIS Health’s Health Plan Weekly and Radar on Drug Benefits since 2018. She also manages AIS Health’s annual executive compensation database for top insurers and Blue Cross and Blue Shield affiliates. Before joining AIS Health, she interned at WBEZ, Al Jazeera English and The New York Times Chinese. She graduated from Missouri School of Journalism with a focus on data journalism and international reporting.